Present and Future Dyslipidemia Therapies for Reducing Cardiovascular Risk and Cardiovascular Disease...

— —

Shirya Rashid (Tenured Associate Professor, Departments of Pharmacology and Medicine, Dalhousie and McMaster Universities, Canada) Shirya Rashid (Tenured Associate Professor, Departments of Pharmacology and Medicine, Dalhousie and McMaster Universities, Canada)

Present and Future Dyslipidemia Therapies for Reducing Cardiovascular Risk and Cardiovascular Disease Incidence

Shirya Rashid (Tenured Associate Professor, Departments of Pharmacology and Medicine, Dalhousie and McMaster Universities, Canada), Shirya Rashid (Tenured Associate Professor, Departments of Pharmacology and Medicine, Dalhousie and McMaster Universities, Canada)

$290.95

Paperback

Forthcoming
Pre-Order now

QTY:

English

Academic Press Inc
01 June 2024

Cardiovascular medicine; Pharmacology

In the last few decades, statins had been widely used to successfully lower ASCVD risk. Despite the efficacy of statins in reducing CVD events in primary and secondary prevention patients, there is still substantial residual risk and initial and recurring CVD events remaining in these patient groups.

Dyslipidemia Therapies for Reducing Cardiovascular Disease Risk provides an overview of the latest research and developments in dyslipidemia therapies to combat elevated lipid levels leading to atherosclerotic cardiovascular disease (ASCVD). A translational medicine approach is used to discuss the background on key lipid disorders in the population leading to cardiovascular disease; clinical trial development of the new drug therapies to combat the lipid disorders and their mechanisms of action; and the target patient groups of the therapies and how they address unmet medical needs in cardiovascular disease/lipid disorders. Contributions from leaders in the dyslipidemia, metabolic and cardiology fields, they offer insights into the research and development and medical backgrounds of the new drug therapies, as well as unpublished information regarding the challenges in unmet medical needs with respect to dyslipidemia in the population, clinical trial development of the therapies and future goals for the therapies.

Edited by: Shirya Rashid (Tenured Associate Professor Departments of Pharmacology and Medicine Dalhousie and McMaster Universities Canada), Shirya Rashid (Tenured Associate Professor, Departments of Pharmacology and Medicine, Dalhousie and McMaster Universities, Canada)
Imprint: Academic Press Inc
Country of Publication: United Kingdom
Dimensions: Height: 229mm, Width: 151mm,
ISBN: 9780323900560
ISBN 10: 0323900569
Pages: 160
Publication Date: 01 June 2024
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Forthcoming

1. The case for updated lower lipid targets for greater cardiovascular risk reduction 2. The role of established therapies for LDL-cholesterol lowering – statins and ezetimibe 3. PCSK9 monoclonal antibodies and LDL-cholesterol lowering 4. PCSK9 siRNAs as novel therapy for elevated LDL-cholesterol in patients at cardiovascular disease risk 5. Bempadoic Acid as a novel pathway targeting LDL-cholesterol 6. The Role of CETP inhibitors in LDL-cholesterol lowering 7. Beyond LDL-cholesterol, Lp(a) as a therapeutic target 8. Beyond LDL-cholesterol, triglycerides as a therapeutic target effectively reduced by icosapent ethyl 9. Beyond LDL-cholesterol, novel targets: apoCIII, MTP, endothelial lipase and AngPTL3 inhibitors

Shirya Rashid has a Ph.D. in Medical Sciences from the University of Toronto. She was a tenured Associate Professor in the Departments of Pharmacology & Medicine at Dalhousie & McMaster Universities in Canada. Her translational research interest is in cardiovascular diseases, focusing on lipid metabolism at the molecular, cellular, mouse in vivo & clinical levels. She was the first to create the PCSK9 gene-deleted mouse model, uncovering the physiological function of PCSK9 in degrading the LDL receptor & leading to the PCSK9 inhibitory drug therapies (eg alirocumab), highly effective in reducing cardiovascular disease. She has 38+ publications (most in high-impact journals), 2 book chapters, 40+ abstracts, 31+ invited & 28+ conference speaker presentations & 8 patents/copyrights.